1035556-41-2

Upstream product

• 1035556-25-2 3-benzyl-5-(2-fluoro-4-nitrophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
• 100-39-0 benzyl bromide 
• 1035556-24-1 3-benzyl-5-chloro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
• 1035556-22-9 3-benzyl-6-(methylamino)pyrimidin-4(3H)-one 
• 1035556-23-0 3-benzyl-5-hydroxy-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
• 1122-67-4 6-(methylamino)pyrimidin-4(3H)-one 

Downstream Products

• 1035556-42-3 5-(4-amino-2-fluorophenylamino)-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
• 1286748-45-5 C₂₁H₁₅F₂IN₄O₂ 
• 1035556-43-4 5-(2-fluoro-4-iodophenylamino)-6-fluoro-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 
• 1035555-62-4 6-fluoro-5-(2-fluoro-4-iodophenylamino)-3-(2-hydroxyethyl)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione 

Relevant academic research and scientific papers

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

A novel 5-phenylamino-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione series of MEK inhibitors has been developed using structure-based drug design. Lead optimization of this series led to the discovery of TAK-733. This was advanced to Phase I clinical studies for cancer treatment.

MAPK/ERK KINASE INHIBITORS

Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.